Plain-English translation of NCT05468073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called (low-dose IL-2) to see if it can help slow down memory and thinking problems in people with early Alzheimer's disease. The medication works by boosting your immune system in a specific way. Researchers will compare people who receive the medication to those who receive a placebo (a dummy injection) to see if the treatment makes a difference.
Current treatments for Alzheimer's disease have limited effectiveness. This trial exists to explore whether this medication, which modifies the immune system, might offer a new way to slow the disease's progression in its early stages.
You will receive 21 injections under the skin over 18 weeks—either the medication or a placebo, decided by random assignment. The first 5 injections happen on consecutive days, followed by a week break, then weekly injections for 16 more weeks. You'll also have brain imaging scans (PET/MRI) at the start and end of treatment. After treatment ends, you'll return for follow-up visits at 6, 12, and 18 months to check how you're doing cognitively and functionally, with a final brain scan at 19 months. The entire study lasts about 18 months from your first injection.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
France